title: Cisplatin-induced bradycardia and the importance of the QT interval.
abstract: Cisplatin is a very common chemotherapeutic agent used in the treatment of gynecologic malignancies, including cervical, ovarian, and endometrial cancers. Bradycardia is a rare, though potentially severe, side effect of this medication. Here we present the case of a young woman with ovarian cancer who demonstrated significant short-lived cardiotoxicity associated with cisplatin treatment.
authors.affiliation: Division of Surgery, Banner MD Anderson Cancer Center, Gilbert, AZ, USA matthew.schlumbrecht@bannerhealth.com.
authors.forename: Matthew P
authors.initials: MP
authors.lastname: Schlumbrecht
authors.affiliation: Division of Pharmacy, Banner MD Anderson Cancer Center, Gilbert, AZ, USA.
authors.forename: Kristen
authors.initials: K
authors.lastname: Hehr
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001919:Bradycardia / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D002945:Cisplatin / Q000009:adverse effects*; D004562:Electrocardiography; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D013997:Time Factors; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin
keywords: Cisplatin; arrhythmia; ovarian cancer